low - Pre-revenue biotech companies are largely insulated from GDP fluctuations as they have no commercial sales exposed to consumer spending or business investment cycles. However, severe recessions can impact ability to raise capital and valuations of unprofitable growth companies. The rare disease focus further reduces economic sensitivity as treatments address critical medical needs regardless of economic conditions.

High sensitivity through multiple channels: (1) Valuation impact - biotech stocks trade on discounted future cash flows, so rising rates compress NPV of projected revenues 5-10 years out, (2) Financing costs - while current debt is minimal (negative D/E suggests equity-financed), future capital raises become more expensive in high-rate environments as investors demand higher returns, (3) Opportunity cost - rising risk-free rates make speculative pre-revenue biotechs less attractive versus bonds. The 10-year Treasury yield directly impacts discount rates used in DCF models for long-duration assets.

growth - Attracts speculative biotech investors willing to accept binary clinical/regulatory risk for potential multi-bagger returns if gene therapies gain approval. The pre-revenue profile, negative margins, and clinical-stage pipeline appeal to high-risk tolerance growth investors, not value or income investors. Typical holders include biotech-focused hedge funds, venture capital crossover funds, and retail investors seeking lottery-ticket exposure to gene therapy upside.